EyeGate Pharma

100 articles about EyeGate Pharma

• EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

  11/8/2021

  Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG).

• EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

  10/26/2021

  EyeGate Pharmaceuticals, Inc. today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. (“Bayon”) and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021.

• EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

  9/8/2021

  EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye.

• EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/12/2021

  EyeGate Pharmaceuticals, Inc., a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities.

• EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  8/10/2021

  EyeGate Pharmaceuticals, Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules, of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share for gross proceeds of approximately $10.75 million, before deducting placement agent’s fees and other offering expenses.

• EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

  7/26/2021

  EyeGate Pharmaceuticals, Inc. announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately.

• EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study

  6/14/2021

  EyeGate Pharmaceuticals, Inc. announced the first patient dosed in phase II proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye.

• EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

  5/12/2021

  EyeGate Pharmaceuticals, Inc., a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, reported its financial results for the quarter ended March 31, 2021 and provided an update on recent corporate and operational activities.

• EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

  4/1/2021

  EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members.

• EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update

  3/25/2021

  EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced financial results for the year ended December 31, 2020 and provided an update on recent corporate and operational activities.

• EyeGate Enters Into Agreement for $8.0 Million Private Placement

  1/6/2021

  EyeGate Pharmaceuticals, Inc., a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, announced that it has entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $8.0 million.

• EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/9/2020

  EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced financial results for the quarter ended September 30, 2020 and provided an update on recent corporate and operational activities.

• EyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that its Chief Executive Officer, Stephen From, will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference, taking place from September 14-16th, 2020.

• EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product

  8/12/2020

  WALTHAM, MA / ACCESSWIRE / August 12, 2020 / EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that it has received positive feedback following its pre-IND meeting with the U.S. Food and Drug Administration and has been provided a path forward for the development of MoxiGel, a combination product for the treatment of bacterial conjunctivitis.

• EyeGate Pharma Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/6/2020

  EyeGate Pharmaceuticals, Inc. announced financial results for the quarter ended June 30, 2020 and provided an update on recent corporate and operational activities.

• EyeGate Pharma to Proceed with PE Pivotal Study

  7/14/2020

  EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that based on feedback from a meeting with the U.S.

• EyeGate Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel Packaging

  6/16/2020

  EyeGate Pharmaceuticals, Inc. announced that it has received positive feedback from the U.S. Food and Drug Administration regarding the requested packaging for EyeGate's Ocular Bandage Gel eye drop.

• 

  EyeGate Implodes as Eye Drug Flunks Phase II Test

  2/5/2018

  EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints.

• EyeGate Promotes Sarah Romano to Chief Financial Officer

  1/4/2018

  Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase.

• EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye

  12/19/2017

  EyeGate Pharma today announced that it has been granted U.S. Patent No. 9,820,935, by the USPTO.